Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
KANZHUN LIMITED Sponsored ADR (BZ) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
KANZHUN LIMITED Sponsored ADR (BZ) - free report >>
Image: Bigstock
Best Momentum Stocks to Buy for April 18th
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, April 18th:
Verrica Pharmaceuticals Inc. (VRCA - Free Report) : This clinical-stage dermatology therapeutics company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 14.4% over the last 60 days.
Verrica Pharmaceuticals Inc. Price and Consensus
Verrica Pharmaceuticals Inc. price-consensus-chart | Verrica Pharmaceuticals Inc. Quote
Verrica’s shares gained 48.3% over the last three months compared with the S&P 500’s advance of 6.6%. The company possesses a Momentum Score of A.
Verrica Pharmaceuticals Inc. Price
Verrica Pharmaceuticals Inc. price | Verrica Pharmaceuticals Inc. Quote
Kanzhun Limited (BZ - Free Report) : This online recruitment platform from China has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 7.3% over the last 60 days.
KANZHUN LIMITED Sponsored ADR Price and Consensus
KANZHUN LIMITED Sponsored ADR price-consensus-chart | KANZHUN LIMITED Sponsored ADR Quote
Kanzhun’s shares gained 18.5% over the last six months compared with the S&P 500’s advance of 11.8%. The company possesses a Momentum Score of A.
KANZHUN LIMITED Sponsored ADR Price
KANZHUN LIMITED Sponsored ADR price | KANZHUN LIMITED Sponsored ADR Quote
Annovis Bio, Inc. (ANVS - Free Report) : This clinical-stage drug platform company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 18.8% over the last 60 days.
Annovis Bio, Inc. Price and Consensus
Annovis Bio, Inc. price-consensus-chart | Annovis Bio, Inc. Quote
Annovis’ shares gained 24.9% over the last three months compared with the S&P 500’s advance of 6.6%. The company possesses a Momentum Score of B.
Annovis Bio, Inc. Price
Annovis Bio, Inc. price | Annovis Bio, Inc. Quote
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.